The hematopoietic transcription factor Spi-1/PU.1 is an oncoprotein participating to the malignant transformation of proerythroblasts in the Friend erythroleukemia or in the erythroleukemic process developed in spi-1 transgenic mice. Overexpression of Spi-1 in proerythroblasts blocks their differentiation. We have shown that Spi-1 promotes the use of the proximal 5 0 -splice site during the E1A premRNA splicing and interferes with the effect of TLS (Translocated in LipoSarcoma) in this splicing assay. TLS was identified from chromosomal translocations in human liposarcoma and acute myeloid leukemia. Here, we determine the function of Spi-1 domains in splicing and in the interference with TLS. In transient transfection assays in erythroid cells, we show that the DNA binding domain cooperates with the transactivation domain or the PEST region of Spi-1 to modify the function of TLS in splicing. Interestingly, the 27 C-terminal amino acids, which determine the DNA binding activity of Spi-1, are necessary for the splicing function of Spi-1 as well as for its ability to interfere with TLS. Finally, we demonstrate that in leukemic proerythroblasts overexpressing Spi-1, TLS has lost its splicing effect. Thus, we hypothesize that oncogenic pathways in proerythroblasts may involve the ability of Spi-1 to alter splicing.
Introduction
Spi-1/PU.1 was initially identified as an oncogene involved in the malignant transformation of proerythroblasts during the erythroleukemia induced by the SFFV (Spleen Focus Forming Virus). Spi-1 insertional mutagenesis leads to the transcriptional activation of spi-1 in the proerythroblast (Moreau-Gachelin et al., 1988) . The oncogenic function of Spi-1 has been deduced from the erythroleukemia that is developed in transgenic mice overexpressing spi-1 in the erythroid lineage . The overexpression of Spi-1 arrests the proerythroblast in its differentiation process without altering its erythropoietin requirement for survival. During normal hematopoiesis, Spi-1/PU.1 appears as a master gene required for the development of both myeloid and B lymphoid lineages (McKercher et al., 1996; Scott et al., 1997) . Spi-1 is a transcription factor of the ETS family. Its ETS domain recognizes DNA on a 5 0 -A/GGAA-3 0 core (Klemsz et al., 1990) . In addition, Spi-1 contains an amino-terminal transactivation domain and a central PEST region (Pongubala et al., 1993) . The transcriptional activity of Spi-1 depends on its combinatorial association within multiprotein complexes. Some of these proteins are ubiquitous factors such as the basal transcription factor TFIID (Hagemeier et al., 1993) and the co-activator/integrator CBP (Yamamoto et al., 1999) . Other Spi-1-interacting partners are tissue-specific as the B lymphoid factor NF-EM5/Pip (Perkel and Atchison, 1998; Brass et al., 1999) , the myeloid regulators c-JUN , AML1 and C/EBPa (Petrovick et al., 1998) and the erythroid transcription factor GATA-1 (Rekhtman et al., 1999; Zhang et al., 1999; Zhang et al., 2000) .
Moreover, we have shown that Spi-1 interacts with proteins containing RNA binding motifs suggesting that Spi-1 belongs to RNA-protein complexes (Hallier et al., 1996; Hallier et al., 1998) . TLS (Translocated in LipoSarcoma), also called FUS, is one of these Spi-1 partners; it was identified in chromosomal translocations in human myxoid liposarcoma, generating a fusion protein between the N-terminal domain of TLS and the transcription factor CHOP, a member of the c/EBP family (Crozat et al., 1993; Rabbitts et al., 1993) . In acute myeloid leukemia, the same region of TLS is fused to the DNA-binding domain of the ETS protein ERG (Shimizu et al., 1993; Ichikawa et al., 1994) . The amino-terminal part of TLS, which is retained in the chimeric proteins, is a region rich in glutamine, serine and tyrosine that behaves as a transcriptional activation domain (Prasad et al., 1994; Zinszner et al., 1994) . The carboxy-terminal region of TLS contains three domains with consensus RNA binding motifs: an RRM (RNA Recognition Motif) and two RGGs (arginine glycine-rich regions). Multiple functions are postulated for TLS. TLS is associated with the RNA polymerase II and the TFIID complexes that participate to pre-mRNA transcription initiation (Bertolotti et al., 1996) . Thus, TLS could be involved in linking transcription initiation and elongation. Moreover, in addition to Spi-1 (Hallier et al., 1998) , TLS interferes with the function of transcription factors such as the NFkB/p65 complex (Uranishi et al., 2001 ) and hormonal nuclear receptors (Powers et al., 1998) . These data agree with a role of TLS in transcriptional regulation. TLS has been biochemically characterized as hPOMp75, a protein involved in homologous DNA pairing and recombination (Baechtold et al., 1999; Bertrand et al., 1999) . This activity fits with the increased sensitivity to ionizing radiation due to chromosome pairing defects during meiosis in the TLS-deficient mice suggesting that TLS could participate to the maintenance of genomic integrity (Kuroda et al., 2000) . Lastly, many data argue for a role of TLS in RNA processing. Indeed, TLS is associated in complexes with RNA polymerase II transcripts and the hnRNP RNA binding proteins A1 and C1/C2 (Zinszner et al., 1994) . TLS is identical to the hnRNP P2 (Calvio et al., 1995) and has been found bound to the AG dinucleotide of the 3 0 -splice site in introns (Wu and Green, 1997) . Its RGG2-3 domain is able to recruit serine-arginine splicing factors (SR) (Yang et al., 1998) , which modulate the selection of alternative splice sites through interactions with RNA splicing enhancers and RNA binding proteins (for a review Fu, 1995; Manley and Tacke, 1996) . We recently observed that TLS is able to recognize RNA in a sequence-specific manner (Lerga et al., 2001) and to promote use of the distal 5 0 -splice site during alternative splicing of an E1A pre-mRNA in erythroid cells (Hallier et al., 1998) . Altogether, these data argue for a role of TLS in pre-mRNA splicing.
Spi-1 interacts physically with TLS and abrogates the effect of TLS on the selection of alternative 5 0 -splice sites in a splicing assay in erythroid cells. Moreover, Spi-1 is able to inhibit in vitro splicing of a b-globin minigene and to induce selection of the proximal 5 0 -splice sites of the E1A pre-mRNA in a splicing assay carried out in erythroid cells (Hallier et al., 1998) . Thus, Spi-1 appears to be able to participate to gene transcription regulation and to interfere with the maturation of pre-mRNA; in that way it could participate to the coordination of transcription with splicing. Such a coupling could involve the direct interaction of transcription factors with splicing factors as described for SF2/ASF, a splicing factor of the SR protein family and the transcriptional co-activator p52 (Ge et al., 1998) .
To further address how the overexpression of Spi-1 leads to the transformation of proerythroblasts, we investigated the molecular mechanisms underlying the interference of Spi-1 with pre-mRNA processing by focusing on the ability of Spi-1 to alter the function of TLS during the process of alternative splicing in erythroid cells. We determined that the activity of Spi-1 in pre-mRNA splicing depends on its DNA binding domain together with a region located into the amino-terminal part of the protein. These domains participate in the interference of Spi-1 with TLS in splicing. In addition, we show that the overexpression of Spi-1 in leukemic proerythroblasts is correlated with a lack of TLS activity in splicing. Thus, we hypothesize that oncogenic pathways in proerythroblasts may involve the ability of Spi-1 to alter splicing.
Results
Different domains of Spi-1 are involved in splicing of E1A pre-mRNA in erythroid cells
The effects of Spi-1 on pre-mRNA splicing were investigated in in vivo transient splicing assays using the adenoviral E1A minigene as a splicing model (Caceres et al., 1994) . According to the presence of three alternative 5 0 -splice sites in the first exon of the E1A pre-mRNA, three major 13S, 12S and 9S mRNAs isoforms are transcribed from E1A minigene ( Figure 1a ). Two minor RNA isoforms (11S and 10S) were also generated that were not taken into account since they arise from double splicing events (Caceres et al., 1994) . Transient transfection experiments of both Spi-1 and E1A expression vectors were performed in the erythroblastic cell line IW1-32 that does not express the germinal spi-1 gene (Figure 6c ). The E1A transcripts were amplified by a radioactive RT-PCR, separated by electrophoresis ( Figure 1b ) and quantified ( Figure 1c ). As previously reported (Hallier et al., 1998) , Spi-1 induced a decrease of the E1A 9S isoform level correlated with an increase of the 13S and/or 12S isoforms, revealing that Spi-1 promotes the choice of the proximal 5 0 -splice site in erythroblastic cells.
To determine the respective contributions of the Spi-1 domains in the selection of the 5 0 -splice sites, the activities of mutant Spi-1 proteins (shown in Figure 2a ) were examined in transient E1A splicing assays. N163-Spi-1 lacks the DNA binding domain, DBD-Spi-1 lacks the transactivation and PEST domains, D101-Spi-1 lacks the transactivation domain (101 N-terminal amino acids) and DPEST-Spi-1 lacks the central region that contains the PEST domain (amino acids 100-163). A nuclear localization signal was added at the N-terminal end of each mutant to be sure proteins enter into the nucleus. All proteins were tagged with an Myc epitope to monitor their expression levels in transfected cells by Western blotting with the anti-Myc epitope antibody (Figure 1d ). Their DNA binding activities were verified (Figure 2d ). In IW1-32 cells transfected either with the DBD-Spi-1 or the N163-Spi-1 constructs, the ratio of E1A isoforms was identical to the one observed in control cells transfected with empty vectors (Figure 1b, c) , showing that neither the DNA binding domain by itself nor the N-terminal region of Spi-1 can reproduce the effect of the entire Spi-1 protein on E1A splicing. In contrast, the DPEST-Spi-1 and D101-Spi-1 mutants induced a decrease of the 9S E1A species counterbalanced by an increase of the 13S and 12S mRNA levels similarly to the wild-type Spi-1 protein. These results indicate that the effect of Spi-1 on the selection of the 5 0 alternative splice site is mediated through the DNA binding domain associated with the transactivation domain or the PEST region.
The Spi-1 ETS domain is necessary but not sufficient to interfere with splicing function of TLS in erythroblastic cells
We have previously shown that TLS increases the expression of the 9S E1A isoform by promoting the use of the distal 5 0 -splice site of E1A pre-mRNA in erythroblastic cells and that this effect is counterbalanced by Spi-1 ( (Hallier et al., 1998, and Figure 2b) . To investigate which domains of Spi-1 affect the splicing function of TLS, transient splicing assays were performed with the mutated forms of Spi-1 expressed in the presence of TLS. The co-expression of DBD-Spi-1 and TLS constructs in IW1-32 cells did not change the pattern of E1A isoforms observed in TLS-transfected cells (Figure 2b ). The same results were observed when the N163-Spi-1 and TLS constructs were co-expressed in IW1-32 cells. Thus, DBD-Spi-1 is not capable to alter the effect of TLS in E1A splicing. However, the Spi-1 DNA binding domain is necessary since N163-Spi-1 has no effect on the increase in 9S induced by TLS. When D101-Spi-1 and TLS constructs were co-transfected in IW1-32 cells, the levels of 13S, 12S and 9S E1A isoforms were identical to those observed in control cells showing that D101-Spi-1 was able to counteract the effect of TLS on promoting the use of the E1A distal 5 0 -splice site. When DPEST-Spi-1 and TLS constructs were cotransfected, the levels of 13S, 12S and 9S isoforms were the same as in cells transfected with either Spi-1 or DPEST-Spi-1 alone. Disappearance of the effect of TLS upon its coexpression with DPEST-Spi-1 did not result from the reduced expression of TLS in these transfected cells, as Western blot analysis showed that TLS levels were comparable in all samples ( Figure 2c ). This suggests that the DPEST-Spi-1 protein is able to prevent the activity of TLS in splicing. Altogether, these data demonstrate that the DNA binding domain associated The C-terminal end of Spi-1 is necessary for its function in splicing and for its interference with the splicing activity of TLS
The above experiments have established that the functions of Spi-1 in both splicing and interference with the splicing function of TLS need its DNA binding domain. To investigate whether the DNA binding activity of Spi-1 could influence these activities, we generated the DCter-Spi-1 mutant that lacks the 27 C-terminal amino acids. The DNA binding of DCterSpi-1 along with that of other Spi-1 mutants was analysed in an electrophoretic mobility shift assay (EMSA) using the CD11b Spi-1 DNA binding site as a probe (Pahl et al., 1993) . Proteins were generated in reticulocyte lysates and their levels were monitored by immunoblotting ( Figure 2d ). Spi-1 induced a shift in probe migration whereas DCter-Spi-1 did not, demonstrating that DCter-Spi-1 was deficient in DNA binding ( Figure 2d ). As expected, D101-Spi-1 and DPEST-Spi-1 induced a shift in CD11b migration while N163-Spi-1 did not. In vitro translated Spi-1 and Spi-1 mutants were incubated with a radiolabeled CD11b oligonucleotide as a probe. DNA-protein complexes were separated by EMSA and analysed by autoradiography (above panel). Proteins were analysed by immunoblotting using the anti-Myc epitope monoclonal antibody (aMT) to ascertain that equal amounts of proteins were used in EMSA (lower panel). Proteins were revealed by enhanced chemiluminescence
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The expression of DCter-Spi-1 in the E1A transient splicing assay did not affect the expression pattern of E1A isoforms (Figures 1c and 2b) , as compared to control cells (c). Moreover, their co-expression with TLS did not alter the ratio of E1A isoforms induced by TLS in IW1-32 cells (Figure 2b ). These results suggest that the DNA binding ability could be required for the role of Spi-1 in splicing and for its interference with the splicing activity of TLS.
The various Spi-1 domains interact with TLS in vivo Then, we investigated the interactions of Spi-1 and TLS in vivo. Nuclear extracts from IW1-32 cells transfected with Spi-1 mutants alone or in the presence of TLS were immunoprecipitated at reduced stringency with Spi-1 or TLS antibodies. Polyclonal antibodies directed against the entire Spi-1 protein were used to immunoprecipitate Spi-1 and its mutants (Delgado et al., 1994) . A polyclonal antibody directed against the 165 N-terminal amino acids of TLS was used to immunoprecipitate TLS (Hallier et al., 1998) . The corresponding preimmune sera were used as control in co-immunoprecipitation assays. Moreover, we checked that TLS was not detected after immunoprecipitation with the Spi-1 antibodies in IW1-32 cells (data not shown and Hallier et al., 1998) . The presence of interacting proteins was assessed by immunoblotting the immunoprecipitates with an antiMyc epitope antibody. As shown in Figure 3 , TLS coimmunoprecipitated either with Spi-1 (lane 3) or with Spi-1 mutants (lanes 6, 9, 12, 15 and 18) when Spi-1 antibody was used. Reciprocal experiments using TLS antibody failed to co-immunoprecipitate the Spi-1 mutants as shown, for example in Figure 3 (lane 20) . The difference in the ability of Spi-1 and TLS antibodies to immunoprecipitate associated proteins could be due to the disruption of Spi-1/TLS complexes by the TLS antibody. Alternatively, the region recognized by the TLS antibodies may not be available in the complex. These results indicate that each Spi-1 domain may be involved in a direct or indirect interaction with TLS in erythroid cells. Nevertheless, such an interaction is not sufficient by itself to induce a functional interference of Spi-1 and TLS in splicing since it is observed with N163-Spi-1, DCter-Spi-1 and DBD-Spi-1 mutants, which do not modify the TLS splicing activity.
The interference of Spi-1 with TLS in splicing occurs mainly through the RGG2-3 domain of TLS TLS contains an N-terminal transactivation domain, an RRM and an RGG RNA binding domain (Figure 4a ). To assess which domains of TLS are required for the functional interference of Spi-1 with TLS in E1A splicing, the Myc-tagged RRM-TLS, RGG2-3-TLS and AD-RGG1-TLS mutants were transfected along with Spi-1 and E1A expression vectors in IW1-32 erythroid cells. Their expression levels and the patterns of E1A isoforms were shown in Figure 4c and b. In cells expressing both AD-RGG1-TLS and Spi-1, the E1A isoforms ratio was identical to the one observed in cells transfected with Spi-1 alone. Thus, AD-RGG1-TLS did not change the Spi-1 activity in E1A splicing, a result that was expected from the lack of function of AD-RGG1-TLS in E1A splicing. The RGG2-3-TLS mutant provoked an increase in the 9S isoform expression although its effect was reduced as compared to wild-type TLS. When RGG2-3-TLS and Spi-1 constructs were coexpressed in erythroid cells, levels of 9S, 12S and 13S were identical to those observed in control cells. As for RRM-TLS, though it induced a faint increase in 9S levels, this effect was no longer detected when it was coexpressed with Spi-1. Thus, Spi-1 interferes with the RRM and RGG2-3 domains of TLS that are involved in promoting the use of the distal 5 0 -splice site of the E1A pre-mRNA. Spi-1 prevents TLS from its binding to RNA We reported that TLS exhibits an RNA recognition specificity, which was determined by the RRM and RGG2-3 domains (Lerga et al., 2001) . Thus, we examined by EMSA whether Spi-1 was able to alter the RNA recognition of TLS. To this end, we compared the binding of TLS to its target GGUG RNA in the presence of increasing Spi-1 amounts. Spi-1 inhibited the specific binding of TLS to its target RNA in a dose-dependent manner ( Figure 5, lanes 1-4) . This inhibition was specific since it was not observed when another ETS protein, Fli-1, was added to compete with TLS (lane 5). It did not involve a competition of Spi-1 for binding to the GGUG RNA probe since Spi-1 by itself did not interact with the TLS target RNA (lane 7). When N163-Spi-1 or DBD-Spi-1 was added in such a TLS RNA binding assay, only DBD-Spi-1 was able to impede the binding of TLS to RNA (lanes 9 and 11). Therefore, these data reveal that Spi-1 by its DNA binding domain is able to prevent the RNA binding of TLS in vitro.
The splicing function of TLS is altered in Friend cells and in spi-1 transgenic proerythroblasts
To further investigate whether the splicing interference of Spi-1 with TLS may have a biological relevance with regard to the erythroleukemic transformation, we analysed the splicing activity of TLS in proerythroblasts that express a high level of Spi-1 as a consequence of either insertional mutagenesis (745-A Friend cells) (Moreau-Gachelin et al., 1988) or transgenesis (606 HS2 cells) (Figure 6c ). The E1A isoforms were analysed in both 606 HS2 and 745-A cells transfected with the TLS expression vector or the empty vector. The same ratios of E1A isoforms were observed in both TLS-transfected and control 745-A and 606 cells (Figure 6a ). To ensure that the absence of TLS splicing effect did not result from an excess of E1A splicing substrate with regard to the expression level of TLS and/or splicing factors in transfected cells, we reduced the amount of E1A reporter gene. When the amount of E1A construct was decreased 30-fold (0.01 versus 0.3 mg) (Figure 6a ), the ratio of 9S, 12S and 13S isoforms was not modified by exogenous TLS. Therefore, these data show that the effect of TLS on the selection of the distal 5 0 -splice site in E1A pre-mRNA is impeded in erythroid cells harboring high levels of endogenous Spi-1 protein.
Discussion
Spi-1 is an oncogenic protein that participates in the malignant transformation of proerythroblasts during Friend erythroleukemia as well as the erythroleukemic process developed in spi-1 transgenic mice (MoreauGachelin et al., 1996) . Overexpression of Spi-1 in proerythroblasts blocks their differentiation, but little is known about the biological significance of the expression of Spi-1 in the proerythroblast. Clearly, the oncogenic potential of Spi-1 depends on high level of Spi-1 in the proerythroblasts suggesting an effect of Spi-1 by a molecular titration mechanism. Functionally, Spi-1/PU.1 is well known as an ETS transcription factor. Our previous observations that Spi-1 can also influence pre-mRNA splicing and interact with some spliceosome components (Hallier et al., 1996 (Hallier et al., , 1998 lead us to consider a function for Spi-1 in pre-mRNA processing.
Indeed, Spi-1 favors the selection of the proximal 5 0 -splice sites whereas TLS favors the selection of the distal 5 0 -splice site during the maturation of E1A pre- Spi-1/PU.1 interferes with TLS splicing function L Delva et al mRNA used as an alternative splicing model. In addition, Spi-1 interacts with TLS and counterbalances the effect of TLS on E1A alternative splicing in erythroid cells (Hallier et al., 1998) . In this report, we describe the contribution of the domains of Spi-1 in premRNA splicing and in the functional interference with TLS. In a transient splicing assay carried out in erythroblastic cells, the Spi-1 mutants deleted of either the transactivation domain (D101-Spi-1) or the PEST domain (DPEST-Spi-1) exhibit a similar effect to that of Spi-1, and both counterbalance the effect of TLS on the selection of alternative 5 0 -splice sites. In contrast, the N163-Spi-1 mutant, which retains the transactivation and PEST domains, as well as the DBD-Spi-1 mutant do not exhibit any activities in splicing or in splicing interference. Thus, the role of Spi-1 in favoring the selection of the proximal 5 0 -splice sites requires a cooperation between the DNA binding domain and one N-terminal domain suggesting that intramolecular interactions occur between the DNA binding and the transactivation and/or PEST regions of Spi-1. Alternatively, they could also indicate that additional partners interacting with each one of these regions are needed for the splicing function of Spi-1 in vivo. Moreover, the interference of Spi-1 with TLS in splicing depends, on the one hand, on the Spi-1 domains involved in splicing and on the other hand on the RRM and RGG2-3 domains of TLS also involved in splicing. It is noticeable that DPEST-Spi-1 inhibits more efficiently TLS splicing effect than D101-Spi-1 does. Such a difference in the abilities of these two proteins to alter the function of TLS in splicing could result from folding differences. It could also reflect their association with different subsets of interacting proteins. A physical interaction is observed between the Spi-1 domains and TLS in coimmunoprecipitation assays, even for Spi-1 mutants (N163-Spi-1 and DBD-Spi-1) that do not interfere with TLS. Thus, the association of Spi-1 and TLS is not sufficient and may require additional partners to be efficient in splicing interference. So far, many Spi-1 partners have been identified in the field of transcriptional regulation, most of them being DNA binding proteins. According to its function in pre-mRNA splicing, Spi-1 also interacts with components of the spliceosome. In addition to TLS (Hallier et al., 1998) and the nuclear ribonucleoprotein p54 nrb (Hallier et al., 1996) , Spi-1 also traps the high nuclear ribonucleoproteins hnRNP A1 and U120, the subunit U1 70K of the snRNP U1 particle and PSF (polypyrimidine tractbinding protein-associated splicing factor) in nuclear extracts (our unpublished data). Thus, these ribonucleoproteins seem to be potential partners in regulating the splicing activity of Spi-1 as well as its splicing interference with TLS. Although it cannot be ruled out that the readout of the splicing assay reflect the average of Spi-1 and TLS independent effects, the ability of Spi-1 to interact with multiple splicing factors strongly argue for a direct interference of Spi-1 on the function of some spliceosome components. The interference of Spi-1 and TLS in splicing may involve a competition between their antagonist splicing activities as described for the antagonist splicing factors, such as hnRNP A1 and the SR protein SF2/ASF (Mayeda and Krainer, 1992; Caceres et al., 1994; Screaton et al., 1995) . Such a competition is modulated by their respective intracellular expression levels. In this way, Spi-1 when overexpressed as it happens in erythroleukemic cells in which Spi-1 expression was forced by transgenesis (MoreauGachelin et al., 1996) or by insertional mutagenesis (Moreau-Gachelin et al., 1989) , may sequester TLS and alter its splicing function.
The function of some splicing factors occurs through their ability to identify intronic or exonic RNA elements within pre-mRNAs. Although the DNA binding domain of Spi-1 was able to interact with polyA þ RNAs and homoribonucleotide polymers polyG (Hallier et al., 1996) , it does not exhibit an RNA recognition specificity (our unpublished data from a SELEX strategy). Moreover, the DNA binding domain by itself is not effective in pre-mRNA splicing. Thus, it is unlikely that the role of Spi-1 in splicing proceeds via recognition of a specific RNA sequence. In contrast, TLS exhibits a recognition specificity for a consensus GGUG RNA motif, which is mainly attributed to the RGG2-3 domain (Lerga et al., 2001) . Spi-1 by its DNA binding domain prevents the binding of TLS to this motif. Since the physical interaction of TLS with Spi-1 involves their respective RNA or DNA binding domains (Hallier et al., 1998) , such an interaction may induce changes in TLS conformation resulting in alteration of its RNA recognition.
Intriguingly, the Spi-1 mutant devoid of DNA binding activity (Dcter Spi-1) is no more able to affect the selection of 5 0 -splice sites in the E1A pre-mRNA. Moreover, it cannot counterbalance the TLS splicing activity. This correlation between the abilities of Spi-1 to bind DNA and to interfere with splicing suggests that Spi-1 may simultaneously participate in regulation of gene transcription and pre-mRNA maturation as recently described for steroid hormone receptors (Auboeuf et al., 2002) . However, the deleted region in Dcter Spi-1 is known to mediate interaction with various regulators including c-Jun, AML1, C/EBPa and GATA (Petrovick et al., 1998; Behre et al., 1999; Nerlov et al., 2000; Zhang et al., 2000) . Thus, it can also be hypothesized that DCter Spi-1 lost an interaction domain for an essential partner in Spi-1 splicing function. Further investigation will be carried out to determine whether the transactivation and splicing functions of Spi-1 are independent or co-ordinated. Strategies are currently in progress to investigate whether various transcriptional promoters targeted by Spi-1 can lead to differences in splicing of downstream transcripts.
With regard to TLS, its N-terminal domain behaves as a transactivation domain and interacts with the large subunit of RNA polymerase II (Bertolotti et al., 1996) . Interestingly, TLS belongs to the TET protein family whose other members EWS, hTAF II 68 (Bertolotti et al., 1996) and Cabeza (Stolow and Haynes, 1995) (Bertolotti et al., 1998) . Thus, TLS may participate in controlling gene transcription. TLS interacts with SR proteins that participate in constitutive and alternative splicing. SR proteins are localized at sites of active transcription and are associated with the RNA polymerase II (Yuryev et al., 1996; Du and Warren, 1997) . The physical links between RNA polymerase II, SR proteins and TLS strongly suggest that TLS is part of both transcriptional and splicing machineries. Transcription and splicing are coordinated processes at the functional and structural levels (Maniatis and Reed, 2002) . In such a context, both Spi-1 and TLS appear as potential effectors in coupling transcription and splicing. Our interest in exploring the functional interference of Spi-1 with TLS stems from the recurrent implication of proteins of both the ETS family and the TET family in oncogenic processes. In the specific chromosomal translocation observed in Ewing sarcoma and primitive neuroectodermal tumors, the N-terminal end of EWS is fused to the ETS protein Fli-1 (Delattre et al., 1992; Ohno et al., 1994) . The ETS domain is required for both splicing and transforming activities of EWS/FLI (Knoop and Baker, 2001) . EWS/FLI inhibits the functions of hnRNP A1 and SR proteins in splicing (Yang et al., 2000; Knoop and Baker, 2001 ). In addition, the region of EWS fused to Fli-1 interacts with the splicing factor U1C involved in the recognition of the 5 0 -splice site by the U1snRNP complex (Knoop and Baker, 2000) . Thus, the oncogenic activity of EWS/FLI is correlated to its splicing function. TLS is involved in chromosomal translocations with the ETS gene Erg-1 in a subset of acute myeloid leukemias (Prasad et al., 1994) . Yang et al. (1998) reported that the interaction between TLS and the SR proteins SC35 and TASR (TLS-Associated Serine-Arginine protein) modifies the TLS function in splicing and that the oncoprotein TLS/ ERG acts as a dominant-negative protein on the ability of TLS to recruit SC35 and TASR (Yang et al., 2000) . Therefore, in tumor cells, the TET/ETS fusion proteins can alter the splicing pathways involving TLS or EWS. Oncogenic events implicating TET and ETS proteins are related to various transformation processes. Molecular mechanisms can lead to the expression of chimeric oncoproteins such as TLS/ERG and EWS/FLI, or to the ectopic expression of the ETS protein Spi-1 able to interfere with TLS. Altogether, these data argue for functional alterations of factors participating in both gene transcription and pre-mRNA processing leading to oncogenesis.
Materials and methods

Plasmid constructs
pCS3-MT, pCS3-MT-E1A, pCS3-MT-Spi-1, pCS3-MT-TLS, pCS3-MT-AD-RGG1, pCS3-MT-RRM, pCS3-MT-RGG2-3, pGEX-Spi-1, pGEX-TLS and pGEX-Fli-1 were previously described (Hallier et al., 1998; Lerga et al., 2001 ). pCS3-MT-N163, pCS3-MT-DBD, pCS3-MT-D101 and pCS3-MT-DCter were generated by PCR amplification of the appropriate regions from the spi-1 cDNA and insertion in the pCS3-MT vector. In all constructs, a nuclear localization signal and 6 copies of an Myc-epitope (MT) were added to the N-terminal part of the proteins as mentioned in Hallier et al. (1998) . pGEX-GST-N163 and pGEX-GST-DBD plasmids encode fusion proteins between GST and Spi-1-amino acids 1-163 and 164-272, respectively.
Cell lines and cell culture
The mouse Friend erythroleukemic cell lines (IW1-32, 745-A) and the spi-1 transgenic 606 HS2 cell line were maintained in a-modified Eagle's medium (a-MEM) (Gibco-BRL) supplemented with 10% fetal calf serum. were used to measure luciferase activity and to analyse protein expression by Western blotting and the rest was used to extract total RNAs. In parallel, 2 Â 10 6 hematopoietic cells were transfected and used for co-immunoprecipitation experiments.
RNA purification and RT-PCR analysis
Total RNAs were prepared and treated with DNase I (Qiagen) as previously described (Hallier et al., 1998) . 1 mg of RNA was retro-transcribed with the Moloney murine leukemia virus SuperscriptII reverse transcriptase (Gibco-BRL) in the presence of 50 mM dNTP and 2 pmol of 3 0 RT E1A primer. The PCR reaction was performed with Taq DNA polymerase (Perkin Elmer) in the presence of a 5 0 E1A primer, which was 5 0 end-labeled with T4 polynucleotide kinase (Boehringer) and [g 32 P ATP] (Amersham), as described elsewhere (Hallier et al., 1998) . The number of PCR cycles was kept to a minimum (18 to 22 cycles) in order to detect signals within the linear range of the assay. Control RT-PCR reactions contained RNA template that had not undergone reverse transcription. E1A RT-PCR products were resolved on 6% polyacrylamide-urea gels, autoradiographied and quantified with ImageQuant on a Molecular Dynamics PhosphorImager. All transfection experiments were repeated at least four times with various vector batches.
Coimmunoprecipitation and immunoblotting
Transfected cells (2 Â 10 6 cells) were lysed in 100 ml of ice-cold HX buffer (20 mM HEPES pH 7.4, 2 mM MgCl 2 , 100 mM NaCl, 0.5% NP40 and protease inhibitor). Cell extracts were supplemented with 420 mM NaCl, stirred gently for 30 min at 41C and centrifuged at 45 000 r.p.m. for 20 min. The nuclear extracts were diluted with an equal volume of HX buffer and incubated with specific antibodies for 2 h at 41C. The immunoprecipitates were bound to protein A Sepharose (Amersham Pharmacia Biotech) and the beads were extensively washed with ice-cold HX buffer. Proteins were boiled in sample loading buffer (62 mM Tris pH 6.8, 2% SDS, 10% glycerol, 0.1% bromophenol blue, 100 mM DTT), then separated by 10% SDS-PAGE and electrotransferred onto Hybond nitrocellulose membranes (Amersham Pharmacia Biotech). Membrane was blocked with 5% non-fat dry milk in 0.1% PBS-Tween20 before incubation with the monoclonal 9E10 antibody directed against the myc-epitope (Santa Cruz Biochemicals, Santa Cruz, CA, USA) in 5% milk 0.1% PBStween20. After three washes in 0.1% PBS-Tween20, the membrane was incubated with HRP-conjugated secondary antibody and finally washed in 0.1% PBS-Tween20. The proteins were visualized by the enhanced chemiluminescence Western blotting detection system (Amersham Pharmacia Biotech).
For direct Western blotting, transfected cells were washed in PBS and 2 Â 10 5 transfected cells/50 ml sample loading buffer were sonicated and boiled.
Electrophoretic mobility shift assay (EMSA)
For DNA binding assay, the various Spi-1 proteins were translated in vitro from CS3 vectors using TNT coupled reticulocyte lysates (Promega). The CD11b probe was 5 0 -labeled with [g 32 P ATP] (5000Ci/mmol), and EMSA were performed as previously described (Ray-Gallet et al., 1995) . For RNA binding assays, the recombinant proteins were produced and purified as previously described (Hallier et al., 1998) . EMSA was carried out with 5 pmol of proteins and 1 pmol of RNA probe. The RNA probe corresponds to the TLS target pre-mRNA transcribed in vitro by the T7 polymerase in the presence of 5 mCi of [g-32 P UTP] (3000 Ci/ mmol) from 100 ng of the DNA template as previously described (Lerga et al., 2001) . The DNA-protein and RNAprotein complexes were submitted to electrophoresis on to native 6% polyacrylamide gels in 0.5 Â Tris-borate-EDTA (TBE) buffer and autoradiographied.
